TL;DR: Fatigue is a highly prevalent symptom of MG with a severe negative impact on quality of life and Physicians treating patients with MG should be aware of this symptom, as it may be treatable with physical or psychological training programs.
TL;DR: The latest findings on dystrophin isoform expression in the brain; specific DMD-associated learning and behavioural difficulties; and imaging and spectroscopy findings relating to brain structure, networks, perfusion and metabolism are reviewed.
TL;DR: Domagrozumab was generally safe and well tolerated in patients with DMD and its open-label extension and Efficacy measures did not support a significant treatment effect.
TL;DR: Analysis showed that individual abnormalhypertrophy factor at baseline could explain the different changes in muscle size among participants, and could be a key component to identify high and low responders to hypertrophy in DM1.
TL;DR: The peak of abilities gained occurred before the age of 5 years while the highest number of lost abilities was found in the group 5-13 years, and a correlation between the HFMSE baseline score and the ordinal number of the items was found.
TL;DR: Future trials should select patients with weakness and fatigability that is completely explained by their myasthenia gravis, use a design that avoids the exclusion of patients with recent changes in medication, and explore the possibilities to completely avoid the use of corticosteroids.
TL;DR: The identified mutations in the J domain cause dominant distal and proximo-distal Myopathy, confirming that mutations in DNAJB6 should be considered in distal myopathy cases.
TL;DR: Longitudinal magnetic resonance imaging identified increased total brain volume in older mdx mice and deficits in hippocampal long-term spatial learning and memory and increased levels of anxiety-related behaviour shown by older m dx mice.
TL;DR: In a multifactorial regression analysis, the antibody status was the only significant predictor for drug free remission, with 60% of patients with antibodies only to clustered AChR achieving this outcome.
TL;DR: It was observed that MG itself was stated as the third most common ultimate cause of death in Swedish MG patients, and there was a strikingly higher likelihood of having influenza/pneumonia as a contributing cause ofdeath.
TL;DR: A case of a man diagnosed with a non-microcytic lung carcinoma who started treatment with a combination of immune checkpoint inhibitors and subsequently developed binocular diplopia, fatigue, mild dyspnea and upper back pain resembling a myasthenia gravis presentation is reported.
TL;DR: The role of brain dystrophin in muscular dystrophy: Implications for clinical care and translational research, 249th ENMC International Workshop, Hoofddorp, The Netherlands, November 29th–December 1st 2019.
TL;DR: Overall, with no stabilization of functional measures observed over 130 weeks, OLEOS did not support significant benefit of olesoxime in patients with SMA, and this open-label extension study further characterizes the safety, tolerability and efficacy of oLESoxime over longer therapy durations.
TL;DR: Investigating factors affecting rate of onset of 5 major FSHD symptoms found shorter D4Z4 repeat length associated with accelerated onset of each symptom, while pregnancy and carrying multiple children to term was associated with slower onset of all muscle symptoms.
TL;DR: Jitter and RNS assessment are valuable tools for diagnosing neuromuscular transmission abnormalities in CMS patients and strongly suggests CMS compared with CPEO and CM.
TL;DR: The data suggest a possible interference in the morphology and function of myofibrillar network by mutated TNPO3, supported by the in silico identification of genes involved in muscle contraction that could help to explain the pathogenic mechanisms of LGMD D2.
TL;DR: It is suggested that isolated precocious pubarche is associated with early-onset insulin resistance linked to severity of muscular atrophy, and this study aimed to provide a comprehensive description of the endocrine manifestations of SMA patients with variable degree of sarcopenia.
TL;DR: The magnitude of changes in MIP and MEP in the treatment group were consistent with the pilot findings but did not achieve statistical significance in comparison to controls, and therefore sham-RMT may not be an optimal control condition for RMT in LOPD.
TL;DR: Overall, IBM patients who used the EMST device demonstrated no improvement in swallowing function and there was also no change in measures of quality of life.
TL;DR: It is suggested that IGF-1 status is associated with insulin resistance in patients with early-onset sarcopenia and the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and IGF- 1.
TL;DR: A combination of QMT and accelerometry may provide a complementary assessment of skeletal muscle function in non-ambulatory boys with DMD and decline significantly over time.
TL;DR: The etiology of skeletal muscle channelopathies in Japan was not identical to previous reports from Western countries, and provided crucial information for genetics as well as future therapeutic interventions.
TL;DR: The findings expand the number of known SIGMAR1 pathogenic variants associated with dHMN, which should be clinically distinguished from ALS, and identify two novel variants in the SIG MAR1 gene in the proband.
TL;DR: The importance of counselling patients and clinicians for the possibility of worsening symptoms during pregnancy or anaesthesia and the careful management of neonates following delivery is highlighted.